USP Is Changing: What Pharmaceutical Manufacturers Should Know

USP <788> Is Changing: What Pharmaceutical Manufacturers Should Know

The United States Pharmacopeia (USP) is implementing revisions to General Chapter <788>, one of the most widely recognized standards for particulate matter testing in injectable products. While the fundamental purpose of the chapter remains unchanged, the revisions provide important clarification regarding the scope of the chapter and reflect the evolving challenges associated with modern pharmaceutical formulations.

For pharmaceutical manufacturers, contract testing laboratories, and quality professionals, understanding these changes is important not only for compliance, but also for evaluating future particulate testing strategies.

What Is USP <788>?

USP <788> establishes requirements for the determination of subvisible particulate matter in injections and parenteral products. The chapter has traditionally focused on the quantification of particles that are not visible to the naked eye, typically using Light Obscuration (LO) and Microscopic Particle Count methods.

For decades, these techniques have served as the industry standard for monitoring particulate contamination in injectable drug products.

What Is Changing?

One of the most notable changes is the proposed renaming of the chapter from:

“Particulate Matter in Injections”

“Subvisible Particulate Matter in Injections.”

While this may appear to be a minor editorial revision, the change provides important clarification regarding the intended scope of the chapter.

The updated title reinforces that USP <788> specifically addresses subvisible particles and is not intended to cover visible particle inspection, which is addressed separately under USP <790>.

This distinction becomes increasingly important as manufacturers develop more complex formulations, including biologics, protein therapeutics, suspensions, and other products that may present unique particle analysis challenges.

Is USP <790> Being Merged into USP <788>?

There has been industry discussion suggesting that USP <790> (Visible Particulates in Injections) may be incorporated into USP <788>. Based on currently available USP publications and revision proposals, there is no indication that USP <790> is being eliminated or formally merged into USP <788>.

Instead, the revisions appear to clarify the relationship between visible and subvisible particulate testing while maintaining separate chapters for each purpose.

The industry trend is moving toward a more integrated particulate control strategy, where visible particle inspection, subvisible particle testing, root-cause investigations, and contamination control programs are considered together as part of an overall quality strategy.

Why These Changes Matter

Although the numerical acceptance criteria remain largely unchanged, the revisions reflect broader trends occurring throughout the pharmaceutical industry.

1. Increased Focus on Biologics

Modern biologic and protein-based therapeutics can present unique particle characterization challenges. Protein aggregates, silicone oil droplets, and translucent particles may behave differently than traditional particulate contaminants.

As these products become more common, manufacturers are increasingly evaluating whether traditional particle counting methods provide sufficient information for effective investigations.

2. Growing Interest in Particle Characterization

Historically, particulate testing has focused primarily on counting particles.

Today, many quality and development teams are asking additional questions:

What type of particle is present?
What is its morphology?
Is it proteinaceous material?
Is it silicone oil?
Is it an environmental contaminant?
What is the likely source?

These questions often require particle characterization techniques beyond simple counting.

3. Alignment with Modern Contamination Control Strategies

Regulatory guidance such as EU GMP Annex 1 has emphasized comprehensive contamination control strategies throughout the manufacturing process.

As a result, organizations are increasingly viewing particulate testing as one component of a larger contamination control and risk management program rather than an isolated compliance activity.

What Does This Mean for Manufacturers?

For most manufacturers, the immediate impact will be limited. Existing testing programs based on USP <788> remain valid and acceptance criteria are not expected to change significantly.

However, the revisions provide an opportunity to review current particulate control strategies and consider whether additional characterization tools may provide value during investigations and product development.

Manufacturers working with biologics, advanced therapeutics, suspensions, or complex formulations may find increasing value in techniques capable of providing information about particle morphology and composition in addition to particle counts.

Looking Ahead

The proposed revisions to USP <788> are part of a broader industry movement toward a deeper understanding of particulate contamination and its potential impact on product quality.

While particle counting remains a critical component of pharmaceutical quality control, there is growing recognition that understanding particle characteristics and potential sources can provide valuable information during investigations and product development.

As injectable products continue to evolve, particulate analysis technologies and testing strategies are likely to evolve alongside them.